Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syndax Pharmaceuticals ( (SNDX) ) has provided an announcement.
On December 18, 2025, the Board of Directors of Syndax Pharmaceuticals approved amendments to the company’s Amended and Restated Bylaws that change how its capital stock is issued and documented. Effective that date, all newly issued shares will be in uncertificated form, while any shares already represented by physical certificates before December 18, 2025, will remain certificated until those certificates are surrendered to the company, signaling a shift toward a fully electronic share record-keeping system that may streamline corporate administration and modernize shareholder documentation practices.
The most recent analyst rating on (SNDX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Syndax Pharmaceuticals stock, see the SNDX Stock Forecast page.
Spark’s Take on SNDX Stock
According to Spark, TipRanks’ AI Analyst, SNDX is a Neutral.
Syndax Pharmaceuticals faces significant risks due to declining revenues, persistent losses, and negative cash flows, which weigh heavily on its overall score. While the balance sheet remains strong with low leverage, the technical indicators suggest a bearish trend. The valuation is unattractive due to negative earnings. Despite these challenges, the recent earnings call provided some positive news with product launches and a strengthened financial position, partially offsetting the negative aspects. Overall, the company’s ability to improve financial performance and achieve market penetration in the face of competition will be crucial for future stock performance.
To see Spark’s full report on SNDX stock, click here.
More about Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies, particularly in oncology and related serious diseases, targeting unmet medical needs in specialized patient populations.
Average Trading Volume: 2,685,767
Technical Sentiment Signal: Buy
Current Market Cap: $1.77B
Find detailed analytics on SNDX stock on TipRanks’ Stock Analysis page.